Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncol Res
Main Authors: Li, Dong, Sun, Fei-fan, Wang, Dan, Wang, Tao, Peng, Jing-jing, Feng, Jian-Qiong, Li, Hua, Wang, Chao, Zhou, Dai-jun, Luo, Hong, Fu, Zeng-qiang, Zhang, Tao
Formato: Artigo
Idioma:Inglês
Publicado: Cognizant Communication Corporation 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751222/
https://ncbi.nlm.nih.gov/pubmed/32560747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504020X15925659763817
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares